-
Trump Threatens Heavy Taxes on US Firms Building Data Centers Abroad
-
Kuwait DGCA Delegation Attends ICAO Assembly in Montreal
-
Gozo Minister Clint Camilleri Appointed CPMR Vice-President for Maritime Affairs
-
Charlie Puth and Ellie Goulding to Headline First Johnnie & Co. Festival in Mumbai
-
ALIX LASERS shareholders remove Michael Sobitsch as managing director in view of the circumstances
-
Maryland Woman Arrested in Decade-Long Cancer Scam Involving Fake Medical Team
-
Panthers Seek NFC South Lead Against Ravens as Baltimore Ends Skid
-
Closing a Business with Payroll Taxes Owed - Clear Start Tax Explains the Trust Fund Recovery Penalty
-
Ondas, Palantir and Regna AI Host Key Defense Technology Leaders to Accelerate the Path from AI Innovation to Fielded Capability
-
Dateline appoints Tony Ferguson as Acting Chairman
-
American Businessman Mark Eric Williams Vindicated in Six-Year, US$150 Million-Plus Litigation Brought by Kuwaiti State Entities
-
AI Search Engineers Says Longer AI Mode Questions Mean Professional Service Firms Should Answer Full Client Questions Directly on Their Pages
-
Arrive AI's Pro Forma Stockholders' Equity Now Above Nasdaq Minimum Requirement Following Recent Transactions
-
Who Does the Best Rhinoplasty in Sarasota?
-
PodcastOne (NASDAQ:PODC) Launches People Pleasers Podcast hosted by Comedians Leah Rudick and Jessica Michelle Singleton
-
Alset AI Closes Non-Brokered Private Placement Offering
-
Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
-
barq Signs MoU with TenPay Global to Enhance Remittances and Digital Payments in China
-
American Resources Corporation and ReElement Technologies Selected as Part of Winning U.S.-Led Consortium for Kenya's Strategic Mrima Hill Critical Minerals Project
-
Ryde Group Ltd Announces Non-Binding Term Sheet for Proposed Minority Investment in Multi Genius Limited and MOU on Technology Collaboration
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 20
-
Tosca's 2026 Sustainability Report Makes the Case for Packaging as Critical Supply Chain Infrastructure
-
The DEA Laid The Trap - And State Marijuana Operators Took The Bait
-
5 Fun Date Night Ideas That Don't Cost a Fortune
-
Cytta Air Expands Military Contracting Expertise - Appoints Rear Admiral James "Gib" Godwin III to Advisory Board
-
APEX FTE Expo 2026 Unites Aviation Leaders in Singapore and Honors Passenger Experience Excellence
-
APEX Honors Aeroméxico CEO Dr. Andrés Conesa with Historic APEX CEO Lifetime Achievement Award
-
Enmarket to Open Newest Eatery Location in Rincon, GA
-
Eylsia Nicolas Hits No. 1 on Groover's Global and US Singer-Songwriter Charts with "One More Moment," as Taglish Preview of "Wake Me Up for Christmas" Passes One Million Views in Under 24 Hours
-
What Is the Best Social Media Platform for Peptides?
-
WhalesBot Advances Creativity-Driven AI and Coding Education Through Pubbo AI
-
Karviva Introduces Unwined Alcohol-Free Malbec and Rose Varieties
-
Tidal Wave Auto Spa Opens New Locations in Murfreesboro, Tennessee and Asheville, North Carolina This Week
-
Peoples Bancorp Announces Cash Dividend
-
Jaguar Health, Inc. Announces Reverse Stock Split
-
Kartoon Studios' Beacon Media Partners With Bandai on Tamagotchi's Landmark 30th Anniversary Times Square Celebration
-
First Phosphate and Zeo Energy Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium
-
Taylor Bank Announces $125,000 Commitment to Diakonia's Supportive Living Campus Capital Campaign
-
AsiaFIN Holdings Corp. Appoints Fortune Angel INC as U.S. Reseller Partner to Expand Its Agentic and Robotic Process Automation SaaS Business Across New York and the East Coast
-
Commonhold Explained: How New Leasehold Ban Changes Property Ownership in England and Wales
-
Factory Worker Dies in Rare Rectal Explosion Incident in Czechia
-
GIRLBAND! Headline Show at Rough Trade Marks National Breakthrough
Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date
SAN DIEGO, CA / ACCESS Newswire / October 29, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the October 15, 2025 Special Meeting of Stockholders of Revelation Biosciences, Inc. (the "Company"), which was adjourned to October 29, 2025 has been canceled due to technical difficulty outside of the Company's control with stockholders being unable to vote all of their shares. The Company has decided to cancel the adjourned Special Meeting scheduled for today, October 29, at 12pm ET and to set a new record date of October 29, 2025 for a new Special Meeting of Stockholders to take place on December 3, 2025. The Company will issue new proxy materials to all stockholders of record as of the new record date in connection with this meeting. The Company encourages all stockholders to vote their shares promptly upon receipt of the proxy materials.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as prevention for acute kidney injury and for the treatment of chronic kidney disease.
For more information, please visit www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
Company Contacts
Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: [email protected]
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: [email protected]
SOURCE: Revelation Biosciences, Inc.
View the original press release on ACCESS Newswire
E.Rodriguez--AT